Rezolute reports Q2 net loss $15.7M; ersodetug gets Breakthrough Therapy, Orphan Drug status

Rezolute, Inc.

2025-Q2 EPS reported -$0.45 vs consensus -$0.22 ▼ miss (-100.5%)

Cash & equivalents $105.3M at Dec 31, 2024 vs $127.1M at June 30, 2024.
Net loss $15.7M for Q2 fiscal 2025 vs $13.9M for same period last year.
FDA granted Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism (HI).
FDA granted Orphan Drug Designation for ersodetug in tumor HI.
Phase 3 sunRIZE study interim analysis planned this quarter; topline results expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.